Helen Louise Collins, CHIEF MEDICAL OFFICER at Enliven Therapeutics, Inc. (ELVN), sold 45,000 shares at $26.17 ($1.2M) on 2026-02-17, disclosed to the SEC on 2026-02-19.
Scheduled sale ($1.2M) by CHIEF MEDICAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| ELVN | SELL | 2026-07-21 | $263K | — | Filing → |
| ELVN | SELL | 2026-06-22 | $219K | — | Filing → |
| ELVN | SELL | 2026-05-20 | $199K | — | Filing → |